Exelixis (EXEL) Long-Term Investments (2010 - 2026)
Exelixis (EXEL) recorded quarterly Long-Term Investments of $649.1 million in Q2 2026, up 7.54% quarter-over-quarter from $603.6 million in Q1 2026, and up 4.8% on a YoY basis from $619.4 million in Q2 2025.
Exelixis (EXEL) Long-Term Investments (2010 - 2026) Analysis & Trends
Exelixis' Long-Term Investments history runs 17 years deep, the most recent figure standing at $649.1 million for Q2 2026.
- In Q2 2026, Long-Term Investments rose 4.8% year-over-year to $649.1 million; the TTM figure through Apr 2026 stood at $649.1 million (up 4.8% YoY), while the FY2026 annual figure was $603.6 million, down 5.29% from the prior year.
- Long-Term Investments was $649.1 million for Q2 2026 at Exelixis, up from $603.6 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $838.6 million in Q2 2023 to a low of $404.5 million in Q2 2022.
- Historically, Long-Term Investments has averaged $625.3 million across 5 years, with a median of $619.4 million in 2025.
- The sharpest annual moves came in 2022 and 2024: Long-Term Investments jumped 103.91% in 2022, then plunged 48.45% in 2024.
- A 5-year view of Long-Term Investments shows it stood at $756.7 million in 2022, then slipped by 3.7% to $728.7 million in 2023, then dropped by 28.17% to $523.4 million in 2024, then increased by 10.48% to $578.3 million in 2025, then climbed by 12.25% to $649.1 million in 2026.
- The last three Long-Term Investments figures came in at $649.1 million (Q2 2026), $603.6 million (Q1 2026), and $578.3 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 649.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 649.14 Mn |
| Jan 2, 2026 | 603.60 Mn |
| Oct 3, 2025 | 578.29 Mn |
| Jul 4, 2025 | 594.65 Mn |
| Apr 4, 2025 | 619.44 Mn |
| Jan 3, 2025 | 637.29 Mn |
| Sep 27, 2024 | 523.42 Mn |
| Jun 28, 2024 | 432.31 Mn |
| Mar 29, 2024 | 629.56 Mn |
| Dec 29, 2023 | 728.72 Mn |
| Sep 29, 2023 | 811.68 Mn |
| Jun 30, 2023 | 838.62 Mn |
| Mar 31, 2023 | 806.62 Mn |
| Dec 30, 2022 | 756.73 Mn |
| Sep 30, 2022 | 551.74 Mn |
| Jul 1, 2022 | 463.89 Mn |
| Apr 1, 2022 | 404.54 Mn |
| Dec 31, 2021 | 371.11 Mn |
| Oct 1, 2021 | 362.22 Mn |
| Jul 2, 2021 | 345.61 Mn |